PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 32945430-11 2020 In addition, HG activated inflammatory factors, such as TNF-alpha, IL-1beta and IL-6; however, their levels were suppressed when cells were treated with FPS-ZM1 or the TXNIP/NLRP3 pathway inhibitor, resveratrol (Res). Resveratrol 199-210 interleukin 6 Homo sapiens 80-84 33859520-0 2021 Oral Resveratrol supplementation attenuates exercise-induced Interleukin-6 but not Oxidative Stress after a high intensity cycling challenge in adults. Resveratrol 5-16 interleukin 6 Homo sapiens 61-74 33461297-1 2021 Recent data have shown anti-inflammatory effects for trans-resveratrol (RSV) and rosmarinic acid (RA) in various immune-competent cell models through reduction of lipopolysaccharide (LPS)-induced interleukin 6 (IL-6) release. Resveratrol 53-70 interleukin 6 Homo sapiens 196-209 33461297-1 2021 Recent data have shown anti-inflammatory effects for trans-resveratrol (RSV) and rosmarinic acid (RA) in various immune-competent cell models through reduction of lipopolysaccharide (LPS)-induced interleukin 6 (IL-6) release. Resveratrol 53-70 interleukin 6 Homo sapiens 211-215 33461297-1 2021 Recent data have shown anti-inflammatory effects for trans-resveratrol (RSV) and rosmarinic acid (RA) in various immune-competent cell models through reduction of lipopolysaccharide (LPS)-induced interleukin 6 (IL-6) release. Resveratrol 72-75 interleukin 6 Homo sapiens 196-209 33461297-6 2021 Next, the IL-6 modulatory effect of 100 muM RSV was studied in LPS-treated immune-competent HGF-1 cells. Resveratrol 44-47 interleukin 6 Homo sapiens 10-14 33461297-7 2021 After 6 h of treatment, RSV reduced the LPS-induced IL-6 gene expression and protein release by -46.2 +- 12.7 and -73.9 +- 2.99%, respectively. Resveratrol 24-27 interleukin 6 Homo sapiens 52-56 33325132-0 2021 Resveratrol treatment reduces expression of MCP-1, IL-6, IL-8 and RANTES in endometriotic stromal cells. Resveratrol 0-11 interleukin 6 Homo sapiens 51-55 33325132-3 2021 In this study, we evaluated the effects of resveratrol treatment on expression of monocyte chemotactic protein-1 (MCP-1), interleukin-6 (IL-6), IL-8, and regulated upon activation, normal T cell expressed and secreted (RANTES) in endometrial stromal cells from patients with endometriosis compared with non-endometriotic controls. Resveratrol 43-54 interleukin 6 Homo sapiens 122-135 33325132-3 2021 In this study, we evaluated the effects of resveratrol treatment on expression of monocyte chemotactic protein-1 (MCP-1), interleukin-6 (IL-6), IL-8, and regulated upon activation, normal T cell expressed and secreted (RANTES) in endometrial stromal cells from patients with endometriosis compared with non-endometriotic controls. Resveratrol 43-54 interleukin 6 Homo sapiens 137-141 33325132-5 2021 Resveratrol treatment significantly reduced gene and protein expression of MCP-1, IL-6, and IL-8 in EuESCs and EESCs compared with CESCs (P < .05-.001, P < .05-.001 and P < .05-<.01, respectively), and this reduction was more noticeable in EESCs than EuESCs (P < .05-<.001). Resveratrol 0-11 interleukin 6 Homo sapiens 82-86 33325132-7 2021 Resveratrol treatment significantly reduced the expression of MCP-1, IL-6, IL-8 and RANTES in EESCs. Resveratrol 0-11 interleukin 6 Homo sapiens 69-73 29802929-7 2018 More importantly, here we show that Resveratrol has the potential to abrogate the secretion of IL-6 by CAFs. Resveratrol 36-47 interleukin 6 Homo sapiens 95-99 32322697-1 2020 Objectives: To evaluate effectiveness of a nasal resveratrol/carboxymethyl-beta-glucan solution compared to nasal saline solution: a) on common cold symptoms by means of a validated measure scale (CARIFS score), b) on Rhinovirus infection and CCL2, CCL5, IL8, IL6, CXCL10 and TLR2 expression in nasal swabs, c) on frequency of relapses after 30 days of follow-up. Resveratrol 49-60 interleukin 6 Homo sapiens 260-263 31483910-8 2020 RESULTS: After treatment with resveratrol, it was found that serum levels of IL-6, IL-1beta, TNF-alpha, IL-18, NF-kappaB, and CRP decreased in treatment group. Resveratrol 30-41 interleukin 6 Homo sapiens 77-81 31376399-7 2019 We demonstrate that the synergistic action of phosphate overload and IL-6 enhances senescence-associated calcification in a p53-dependent manner and is inhibited by an anti-aging agent (resveratrol) in a dose-dependent manner. Resveratrol 186-197 interleukin 6 Homo sapiens 69-73 30384152-10 2019 Intriguingly, both resveratrol and JNK inhibitor SP600125 suppressed TNFalpha-induced IL6 and IL8 mRNA expression (P < 0.05). Resveratrol 19-30 interleukin 6 Homo sapiens 86-89 31405706-7 2019 CONCLUSIONS: It is suggested that daily consumption of resveratrol supplement may not change TNFalpha, TAC and CAL, but it would be beneficial in reducing serum levels of IL6. Resveratrol 55-66 interleukin 6 Homo sapiens 171-174 31165327-10 2019 In conclusion, combination of resveratrol and silymarin could significantly inhibit inflammatory effects of histamine on cultured HGFs by reduction of IL-6, IL-8, TPA-1, and TNF-alpha. Resveratrol 30-41 interleukin 6 Homo sapiens 151-155 29704506-10 2018 RSV also inhibited inflammation injury of HaCaT cells by reducing productions of IL-6, IL-8, and TNF-alpha. Resveratrol 0-3 interleukin 6 Homo sapiens 81-85 28455791-4 2017 Resveratrol abolished HSC-induced angiogenesis and suppressed ROS production and IL-6 and CXCR4 receptor expression in HepG2 cells by down-regulating Gli-1 expression. Resveratrol 0-11 interleukin 6 Homo sapiens 81-85 29710474-0 2018 Resveratrol inhibits Interleukin-6 induced invasion of human gastric cancer cells. Resveratrol 0-11 interleukin 6 Homo sapiens 21-34 29710474-6 2018 In gastric cancer cell line model, we found that non-cytotoxic concentration of resveratrol inhibited the Interleukin-6 induced SGC7901 cell invasion and matrix metalloproteinases activation. Resveratrol 80-91 interleukin 6 Homo sapiens 106-119 29710474-7 2018 Our studies showed that IL-6 induced SGC7901 cell invasion depends on the Raf/MAPK pathway activation, resveratrol could inhibit this pathway activation. Resveratrol 103-114 interleukin 6 Homo sapiens 24-28 29710474-8 2018 We further showed that resveratrol inhibits the IL-6 induced metastasis by vein injection of luciferase-labeled cancer cells. Resveratrol 23-34 interleukin 6 Homo sapiens 48-52 29710474-9 2018 In conclusion, these results indicate that Interleukin-6 promotes tumor growth and metastasis in gastric cancer, resveratrol has the potential to prevent the Interleukin-6 induced gastric cancer metastasis by blocking the Raf/MAPK signaling activation. Resveratrol 113-124 interleukin 6 Homo sapiens 158-171 28204817-0 2017 Resveratrol inhibits the IL-1beta-induced expression of MMP-13 and IL-6 in human articular chondrocytes via TLR4/MyD88-dependent and -independent signaling cascades. Resveratrol 0-11 interleukin 6 Homo sapiens 67-71 28429008-6 2017 We found that the resveratrol analogues also significantly inhibited Akt and MAPK signalling and reduced the migration of IL-6 and EGF-treated cells. Resveratrol 18-29 interleukin 6 Homo sapiens 122-126 28500309-5 2017 Resveratrol reduced sFlt-1, sFlt-1 e15a and soluble endoglin secretion from primary trophoblasts and HUVECs and reduced mRNA expression of pro-inflammatory molecules NFkappaB, IL-6 and IL-1beta in trophoblasts. Resveratrol 0-11 interleukin 6 Homo sapiens 176-180 28467474-0 2017 Tonic suppression of PCAT29 by the IL-6 signaling pathway in prostate cancer: Reversal by resveratrol. Resveratrol 90-101 interleukin 6 Homo sapiens 35-39 28467474-8 2017 In addition, we show that resveratrol is a potent stimulator of PCAT29 expression under basal condition and reversed the down regulation of this lncRNA by IL-6. Resveratrol 26-37 interleukin 6 Homo sapiens 155-159 29285030-10 2017 Resveratrol significantly inhibited LPS-induced IL-6 and IL-8 secretion by HGFs, but silymarin did not show such a significant effect. Resveratrol 0-11 interleukin 6 Homo sapiens 48-52 28278187-6 2017 Treatment with resveratrol significantly reduced the expression and secretion of pro-inflammatory cytokines IL-6, IL-1alpha, IL-1beta and pro-inflammatory chemokines IL-8 and MCP-1 in human placenta and omental and subcutaneous adipose tissue. Resveratrol 15-26 interleukin 6 Homo sapiens 108-112 26687643-0 2016 Resveratrol reduces IL-6 and VEGF secretion from co-cultured A549 lung cancer cells and adipose-derived mesenchymal stem cells. Resveratrol 0-11 interleukin 6 Homo sapiens 20-24 27787915-0 2017 Resveratrol inhibits IL-6-induced ovarian cancer cell migration through epigenetic up-regulation of autophagy. Resveratrol 0-11 interleukin 6 Homo sapiens 21-25 27787915-7 2017 On opposite, Resveratrol could counteract the IL-6 induction of cell migration in ovarian cancer cells through induction of autophagy in the cells at the migration front, which was paralleled by up-regulation of ARH-I and down-regulation of STAT3 expression. Resveratrol 13-24 interleukin 6 Homo sapiens 46-50 27478543-7 2016 Increased mRNA levels of tumor necrosis factor-alpha and interleukin (IL)-6 induced by LPS were significantly attenuated, and decreased levels of IL-10 and brain-derived neurotrophic factor were significantly restored by resveratrol and miR-Let7A overexpression, respectively, or in combination. Resveratrol 221-232 interleukin 6 Homo sapiens 57-75 26296578-8 2015 Resveratrol exerted a high, dose-dependent, antiviral activity against HRV-16 replication and reduced virus-induced secretion of IL-6, IL-8 and RANTES to levels similar to that of uninfected nasal epithelia. Resveratrol 0-11 interleukin 6 Homo sapiens 129-133 26410779-5 2015 The analysis of pro-inflammatory cytokines release by ELISA revealed that resveratrol, lipoic acid melatonin and Co-Q10 inhibited the BBB endothelial release of pro-inflammatory cytokines IL-6 and IL-8, reduced (not Co-Q10) CSE-induced up-regulation of Platelet Cell Adhesion Molecule-1 (PECAM-1), Vascular Cell Adhesion Molecule-1 (VCAM-1) & E-selectin and inhibited monocytes-endothelial cell adhesion. Resveratrol 74-85 interleukin 6 Homo sapiens 188-192 26160960-6 2015 The cultivation in resveratrol preserved the CB-HSC phenotype in vitro most efficiently and was ~2 times more potent than commonly used cytokine conditions (including stem cell factor, thrombopoietin, Fms-related tyrosine kinase 3 ligand, interleukin-6) and the recently established serum-free culture, including IGFBP2 and angiopoietin-like 5. Resveratrol 19-30 interleukin 6 Homo sapiens 239-252 26190093-4 2015 Resveratrol can both decrease the secretion of proinflammatory cytokines (e.g., IL-6, IL-8, and TNF-alpha) and increase the production of anti-inflammatory cytokines; it also decreases the expression of adhesion proteins (e.g., ICAM-1) and leukocyte chemoattractants (e.g., MCP-1). Resveratrol 0-11 interleukin 6 Homo sapiens 80-84 25576658-3 2015 In this paper we demonstrate that in LPS-stimulated microglia resveratrol pretreatment reduced, in a dose-dependent manner, pro-inflammatory cytokines IL-1beta, TNF-alpha and IL-6 mRNA expression and increased the release of anti-inflammatory interleukin (IL)-10. Resveratrol 62-73 interleukin 6 Homo sapiens 175-179 25701505-4 2015 Treatment of LPS-stimulated macrophages with 70kGy gamma-irradiated resveratrol resulted in a dose-dependent decrease in iNOS-mediated NO, PGE2, and pro-inflammatory cytokine level, such as TNF-alpha, IL-6 and IL-1beta. Resveratrol 68-79 interleukin 6 Homo sapiens 201-205 25926797-3 2015 In this study, we used an in vitro model of human adipose tissue inflammation to examine the effects of resveratrol on the production of the inflammatory cytokines interleukin 6 (IL-6), IL-8, and monocyte chemoattractant protein 1 (MCP-1). Resveratrol 104-115 interleukin 6 Homo sapiens 164-177 25926797-3 2015 In this study, we used an in vitro model of human adipose tissue inflammation to examine the effects of resveratrol on the production of the inflammatory cytokines interleukin 6 (IL-6), IL-8, and monocyte chemoattractant protein 1 (MCP-1). Resveratrol 104-115 interleukin 6 Homo sapiens 179-183 25926797-4 2015 We found that resveratrol reduced IL-6, IL-8, and MCP-1 levels in a concentration-dependent manner in adipocytes under inflammatory conditions. Resveratrol 14-25 interleukin 6 Homo sapiens 34-38 24771768-5 2014 Furthermore, the ability of resveratrol to suppress interleukin-6 transcription was shown to require ERalpha and several ERalpha coregulators, suggesting that ERalpha functions as a primary conduit for resveratrol activity.DOI: http://dx.doi.org/10.7554/eLife.02057.001. Resveratrol 28-39 interleukin 6 Homo sapiens 52-65 25414773-0 2014 Resveratrol Inhibits IL-6-Induced Transcriptional Activity of AR and STAT3 in Human Prostate Cancer LNCaP-FGC Cells. Resveratrol 0-11 interleukin 6 Homo sapiens 21-25 25414773-4 2014 In the present study, we examined the effect of resveratrol, a phytoalexin present in grapes, on the reporter gene activity of AR and STAT3 in human prostate cancer (LNCaP-FGC) cells stimulated with interleukin-6 (IL-6) and/or dihydrotestosterone (DHT). Resveratrol 48-59 interleukin 6 Homo sapiens 199-212 25414773-4 2014 In the present study, we examined the effect of resveratrol, a phytoalexin present in grapes, on the reporter gene activity of AR and STAT3 in human prostate cancer (LNCaP-FGC) cells stimulated with interleukin-6 (IL-6) and/or dihydrotestosterone (DHT). Resveratrol 48-59 interleukin 6 Homo sapiens 214-218 25414773-7 2014 Resveratrol significantly attenuated IL-6-induced STAT3 transcriptional activity, and DHT- or IL-6-induced AR transcriptional activity. Resveratrol 0-11 interleukin 6 Homo sapiens 37-41 25414773-9 2014 Furthermore, the production of prostate-specific antigen (PSA) was decreased by resveratrol in the DHT-, IL-6- or DHT plus IL-6-treated LNCaP-FGC cells. Resveratrol 80-91 interleukin 6 Homo sapiens 105-109 25414773-9 2014 Furthermore, the production of prostate-specific antigen (PSA) was decreased by resveratrol in the DHT-, IL-6- or DHT plus IL-6-treated LNCaP-FGC cells. Resveratrol 80-91 interleukin 6 Homo sapiens 123-127 25414773-10 2014 Taken together, the inhibitory effects of resveratrol on IL-6- and/or DHT-induced AR transcriptional activity in LNCaP prostate cancer cells are partly mediated through the suppression of STAT3 reporter gene activity, suggesting that resveratrol may be a promising therapeutic choice for the treatment of prostate cancer. Resveratrol 42-53 interleukin 6 Homo sapiens 57-62 25414773-10 2014 Taken together, the inhibitory effects of resveratrol on IL-6- and/or DHT-induced AR transcriptional activity in LNCaP prostate cancer cells are partly mediated through the suppression of STAT3 reporter gene activity, suggesting that resveratrol may be a promising therapeutic choice for the treatment of prostate cancer. Resveratrol 234-245 interleukin 6 Homo sapiens 57-62 23981542-10 2014 Resveratrol was superior to dexamethasone in reducing CCL-2, IL-6 and IL-8 in LTA-exposed HASMCs of patients with COPD. Resveratrol 0-11 interleukin 6 Homo sapiens 61-65 23981054-7 2014 RSV reduced Kupffer cells recruitment, the expressions of tumor necrosis factor-alpha and interleukin-6, but not interleukin-10. Resveratrol 0-3 interleukin 6 Homo sapiens 90-103 24266263-6 2013 Pre- and co-treatments with RSV-LNC were able to protect cultures against ROS formation and cell death induced by Abeta, possibly through sustained blocking of TNF-alpha, IL-1beta, and IL-6 release. Resveratrol 28-31 interleukin 6 Homo sapiens 185-189 23661232-6 2013 Resveratrol significantly decreased both basal and interferon-gamma (IFN-gamma) (200 ng/ml)-stimulated levels of MCP-1, IL-6, and IL-8 and significantly attenuated both basal and IFN-gamma-stimulated activity of ERK. Resveratrol 0-11 interleukin 6 Homo sapiens 120-124 22748497-5 2013 In contrast, resveratrol decreased the expression of pro-inflammatory genes IL-6 (interleukin-6) and MCP-1 (monocyte chemoattractant protein-1). Resveratrol 13-24 interleukin 6 Homo sapiens 76-80 22748497-5 2013 In contrast, resveratrol decreased the expression of pro-inflammatory genes IL-6 (interleukin-6) and MCP-1 (monocyte chemoattractant protein-1). Resveratrol 13-24 interleukin 6 Homo sapiens 82-95 23661232-0 2013 Inhibitory effects of resveratrol on MCP-1, IL-6, and IL-8 production in human coronary artery smooth muscle cells. Resveratrol 22-33 interleukin 6 Homo sapiens 44-48 23661232-5 2013 Basal levels of monocyte chemoattractant protein-1 (MCP-1), interleukin (IL)-6, and IL-8 were significantly decreased in the presence of resveratrol at 1-50 muM in a concentration-dependent manner and were significantly decreased in the presence of U0126, an ERK inhibitor. Resveratrol 137-148 interleukin 6 Homo sapiens 60-78 23661232-8 2013 Therefore, resveratrol is thought to inhibit production of MCP-1, IL-6, and IL-8 in HCASMCs through attenuating ERK activity. Resveratrol 11-22 interleukin 6 Homo sapiens 66-70 23262029-10 2013 Further, over-expression of Sirt1 or treatment with the Sirt1 activator resveratrol blocked the increase in Il-6 transcription by MVNP. Resveratrol 72-83 interleukin 6 Homo sapiens 108-112 23844973-0 2013 Resveratrol, a sirtuin 1 activator, increases IL-6 production by peripheral blood mononuclear cells of patients with knee osteoarthritis. Resveratrol 0-11 interleukin 6 Homo sapiens 46-50 23844973-8 2013 After resveratrol treatment, no changes in TNFalpha or IL-8 levels were found, but a significant dose-dependent increase in IL-6 levels was demonstrated in patients with osteoarthritis, but not controls. Resveratrol 6-17 interleukin 6 Homo sapiens 124-128 23844973-11 2013 Ex vivo treatment of peripheral blood mononuclear cells with resveratrol was associated with a dose-dependent increase in IL-6 levels only in patients with osteoarthritis. Resveratrol 61-72 interleukin 6 Homo sapiens 122-126 23533494-8 2013 Resveratrol significantly decreased CSC-related Shh expression, Gli-1 nuclear translocation, and cell viability in IL-6-treated HL-60 cells and had synergistic effect with Shh inhibitor cyclopamine on inhibiting cell growth. Resveratrol 0-11 interleukin 6 Homo sapiens 115-119 23218986-3 2013 Resveratrol, incubated with non-stimulated mononuclear cells, caused a certain reduction of IL-6, IL-1ra and IL-10, and a moderate increase of TNFalpha release. Resveratrol 0-11 interleukin 6 Homo sapiens 92-96 23533494-10 2013 IL-6 stimulated the growth of AML cells through Shh signaling, and this effect might be blocked by resveratrol. Resveratrol 99-110 interleukin 6 Homo sapiens 0-4 21587103-10 2011 RESULTS: In vitro, resveratrol exhibited an anti-inflammatory and anticatabolic effect on the messenger RNA and protein level for IL-6, IL-8, MMP1, MMP3 and MMP13. Resveratrol 19-30 interleukin 6 Homo sapiens 130-134 22118570-5 2012 Resveratrol preferentially inhibited nuclear factor kappa-light-chain-enhancer of activated B cells (NF-kappaB) activation upon LPS stimulation by interfering with IKK and IkappaB phosphorylation, an effect that potently reduced the transcriptional stimulation of several NF-kappaB target genes, including tumor necrosis factor-alpha and interleukin-6. Resveratrol 0-11 interleukin 6 Homo sapiens 338-351 22118570-8 2012 Resveratrol treatment also prevented the pro-inflammatory effect of fibrillar Abeta on macrophages by potently inhibiting the effect of Abeta on IkappaB phosphorylation, activation of STAT1 and STAT3, and on tumor necrosis factor-alpha and interleukin-6 secretion. Resveratrol 0-11 interleukin 6 Homo sapiens 240-253 20036937-6 2010 Administration of resveratrol can inhibit NF-kappaB activity as well as reduce the concentrations of TNF-alpha, IL-6 and IL-1. Resveratrol 18-29 interleukin 6 Homo sapiens 112-116 21186817-4 2011 The results showed that p-coumaric acid, quercetin, and resveratrol have greater inhibition (p < 0.05) of a TNF-alpha-induced increase in the production of interleukin-6 (IL-6) among 21 tested polyphenolic compounds. Resveratrol 56-67 interleukin 6 Homo sapiens 159-172 21186817-4 2011 The results showed that p-coumaric acid, quercetin, and resveratrol have greater inhibition (p < 0.05) of a TNF-alpha-induced increase in the production of interleukin-6 (IL-6) among 21 tested polyphenolic compounds. Resveratrol 56-67 interleukin 6 Homo sapiens 174-178 20844277-10 2011 The SIRT1 activators resveratrol and SRT1720 significantly decreased LPS-induced TNF, IL6, and IL8 gene expression and release and PTGS2 mRNA expression and resultant prostaglandin (PG) E(2) and PGF(2alpha) release from human gestational tissues. Resveratrol 21-32 interleukin 6 Homo sapiens 86-89 20463039-10 2010 Furthermore, resveratrol down-regulated the expression and secretion of interleukin-6 and interleukin-8. Resveratrol 13-24 interleukin 6 Homo sapiens 72-85 20578705-9 2010 Incubation of ARPE-19 cells with 33 mM glucose in the presence of 0-10 microM trans-resveratrol dose-dependently inhibited VEGF, TGF-beta1, COX-2, IL-6, and IL-8 accumulation, PKCbeta activation, and Cx43 degradation and enhanced GJIC. Resveratrol 78-95 interleukin 6 Homo sapiens 147-151 19416633-6 2009 Resveratrol significantly inhibited the PMA plus A23187-induction of inflammatory cytokines such as tumour necrosis factor (TNF)-alpha, interleukin (IL)-6 and IL-8. Resveratrol 0-11 interleukin 6 Homo sapiens 136-154 19416633-10 2009 Resveratrol suppressed the expression of TNF-alpha, IL-6, IL-8 and COX-2 through a decrease in the intracellular levels of Ca2+ and ERK 1/2, as well as activation of NF-kappaB. Resveratrol 0-11 interleukin 6 Homo sapiens 52-56 18776171-3 2009 RSV blocked 10,12 CLA induction of the inflammatory response by preventing activation of extracellular signal-related kinase and induction of inflammatory gene expression (i.e., IL-6, IL-8, IL-1beta) within 12 h. Similarly, RSV suppressed 10,12 CLA-mediated activation of the inflammatory prostaglandin pathway involving phospholipase A(2), cyclooxygenase-2, and PGF(2alpha). Resveratrol 0-3 interleukin 6 Homo sapiens 178-182 19027816-6 2009 Resveratrol treatment effectively prevented increased production of intracellular reactive oxygen species (iROS) and inflammatory markers (IL1alpha, IL6, IL8, and ELAM-1), and reduced expression of the senescence markers sa-beta-gal, lipofuscin, and accumulation of carbonylated proteins. Resveratrol 0-11 interleukin 6 Homo sapiens 149-152 17967414-6 2007 Resveratrol effectively reversed the secretion and mRNA expression of the atherogenic adipokines, PAI-1 and IL-6, induced by TNF-alpha. Resveratrol 0-11 interleukin 6 Homo sapiens 108-112 18598184-8 2008 Resveratrol at concentrations > or =50 micromol/mL significantly inhibited IL-8 and IL-6 production. Resveratrol 0-11 interleukin 6 Homo sapiens 87-91 18549505-13 2008 Curcumin and resveratrol treatment inhibited NF-kappaB activation and resulted in a reduction of TNF-alpha, IL-1beta, IL-6, and COX-2 gene expression (IC50 = 2 muM) and a reduction of secreted IL-6 and PGE2 (IC50 ~ 20 muM). Resveratrol 13-24 interleukin 6 Homo sapiens 118-122 18549505-13 2008 Curcumin and resveratrol treatment inhibited NF-kappaB activation and resulted in a reduction of TNF-alpha, IL-1beta, IL-6, and COX-2 gene expression (IC50 = 2 muM) and a reduction of secreted IL-6 and PGE2 (IC50 ~ 20 muM). Resveratrol 13-24 interleukin 6 Homo sapiens 193-197 18209571-10 2008 LPS-induced IL-6 promoter activation was also prevented by pretreatment with epigallocatechin 3-gallate, curcumin, and resveratrol. Resveratrol 119-130 interleukin 6 Homo sapiens 12-16 17388968-3 2007 OBJECTIVES: In the present study, we evaluated the effect of various wine polyphenolic compounds and several active synthetic derivatives of resveratrol on the inflammatory cytokines (IL-1beta + IL-6)-induced CRP expression in Hep3B cells. Resveratrol 141-152 interleukin 6 Homo sapiens 195-199 16973825-9 2006 In TNF-alpha-treated HCAECs, resveratrol (in the submicromolar range) significantly attenuated expression of NF-kappaB-dependent inflammatory markers inducible nitric oxide synthase, IL-6, bone morphogenetic protein-2, ICAM-1, and VCAM. Resveratrol 29-40 interleukin 6 Homo sapiens 183-187 17164350-8 2007 Resveratrol inhibited both the constitutive and the interleukin 6-induced activation of STAT3. Resveratrol 0-11 interleukin 6 Homo sapiens 52-65 16150460-0 2005 Resveratrol suppresses IL-6-induced ICAM-1 gene expression in endothelial cells: effects on the inhibition of STAT3 phosphorylation. Resveratrol 0-11 interleukin 6 Homo sapiens 23-27 16490592-8 2006 Resveratrol also down-regulated the expression of NF-kappaB-regulated gene products by Western blot analysis, gelatin zymography, and enzyme-linked immunosorbent assay, including interleukin-6, Bcl-2, Bcl-xL, XIAP, c-IAP, vascular endothelial growth factor (VEGF), and matrix metalloproteinase-9 (MMP-9), which modulates an array of signals controlling cellular survival and proliferation and tumor promotion. Resveratrol 0-11 interleukin 6 Homo sapiens 179-192 16150460-3 2005 In this study we tested the effects of resveratrol upon both IL-6-induced ICAM-1 gene expression and its underlying signaling pathways in endothelial cells (ECs). Resveratrol 39-50 interleukin 6 Homo sapiens 61-65 16150460-4 2005 Resveratrol was found to inhibit both TNFalpha- and IL-6-induced ICAM-1 gene expression at the promoter, transcriptional and protein levels. Resveratrol 0-11 interleukin 6 Homo sapiens 52-56 16150460-5 2005 Resveratrol also abrogates the tyr705 phosphorylation of STAT3 in IL-6-treated ECs, in a dose- and time-dependent manner. Resveratrol 0-11 interleukin 6 Homo sapiens 66-70 16150460-9 2005 Conversely, exposure of ECs to a NOS inhibitor reversed the effects of resveratrol upon IL-6-induced STAT3 phosphorylation. Resveratrol 71-82 interleukin 6 Homo sapiens 88-92 16150460-11 2005 In summary, we demonstrate for the first time that resveratrol inhibits IL-6-induced ICAM-1 gene expression, in part, by interfering with Rac-mediated pathways via the attenuation of STAT3 phosphorylation. Resveratrol 51-62 interleukin 6 Homo sapiens 72-76 15135313-4 2004 When macrophages were primed with IFN-gamma, resveratrol suppressed the expression of HLA-ABC, HLA-DR, CD80, CD86 and inhibited production of TNF-alpha, IL-12, IL-6 and IL-1beta induced by LPS. Resveratrol 45-56 interleukin 6 Homo sapiens 160-164 15517885-4 2004 Resveratrol has been shown to suppress the activation of several transcription factors, including NF-kappaB, AP-1 and Egr-1; to inhibit protein kinases including IkappaBalpha kinase, JNK, MAPK, Akt, PKC, PKD and casein kinase II; and to down-regulate products of genes such as COX-2, 5-LOX, VEGF, IL-1, IL-6, IL-8, AR and PSA. Resveratrol 0-11 interleukin 6 Homo sapiens 303-307 34321087-0 2021 Resveratrol protects human nucleus pulposus cells from degeneration by blocking IL-6/JAK/STAT3 pathway. Resveratrol 0-11 interleukin 6 Homo sapiens 80-84 11108930-0 2001 Resveratrol inhibits interleukin-6 production in cortical mixed glial cells under hypoxia/hypoglycemia followed by reoxygenation. Resveratrol 0-11 interleukin 6 Homo sapiens 21-34 11108930-7 2001 Among the antioxidants studied, only resveratrol suppressed IL-6 gene expression and protein secretion in mixed glial cultures under hypoxia/hypoglycemia followed by reoxygenation. Resveratrol 37-48 interleukin 6 Homo sapiens 60-64 34917160-8 2021 Finally, six genes, namely, CXCL1, HIF1A, IL-6, MMP3, NOX4, and PTGS2, were selected to validate the treatment effects of the resveratrol. Resveratrol 126-137 interleukin 6 Homo sapiens 42-46 34917160-10 2021 In addition, in these chondrocytes, CXCL1, HIF1A, IL-6, MMP3, NOX4, and PTGS2 were reduced considerably, but HIF1A was significantly increased after resveratrol treatment. Resveratrol 149-160 interleukin 6 Homo sapiens 50-54 34917160-11 2021 Conclusions: Our data indicates that CXCL1, HIF1A, IL-6, MMP3, NOX4, and PTGS2 are all targets of resveratrol therapy. Resveratrol 98-109 interleukin 6 Homo sapiens 51-55 34859370-7 2022 RESULTS: Our results demonstrated that resveratrol significantly reduced cell proliferation and enhanced chemosensitivity in breast cancer cells by inhibiting production of IL-6 and STAT3 activation. Resveratrol 39-50 interleukin 6 Homo sapiens 173-177 34859370-9 2022 Further, resveratrol decreased IL-6 levels in LPS-treated differentiated macrophages. Resveratrol 9-20 interleukin 6 Homo sapiens 31-35 34859370-11 2022 CONCLUSION: This study revealed that resveratrol inhibited breast cancer cell proliferation by promoting M1/M2 macrophage polarization ratio and suppressing IL-6/pSTAT3 pathway. Resveratrol 37-48 interleukin 6 Homo sapiens 157-161 34831435-2 2021 Our previous studies demonstrated that resveratrol (RV), a nutraceutical and caloric restriction mimetic with tumor-suppressive properties, counteracts cancer cell motility induced by stromal IL-6 by upregulating autophagy. Resveratrol 39-50 interleukin 6 Homo sapiens 192-196 34831435-2 2021 Our previous studies demonstrated that resveratrol (RV), a nutraceutical and caloric restriction mimetic with tumor-suppressive properties, counteracts cancer cell motility induced by stromal IL-6 by upregulating autophagy. Resveratrol 52-54 interleukin 6 Homo sapiens 192-196 34303665-1 2021 The aim of the current study was to perform a meta-analysis of randomized clinical trials regarding the effect of resveratrol in decreasing the levels of inflammatory cytokines, including interleukin (IL)-1, IL-6, IL-8, and tumor necrosis factor (TNF)-alpha in a combination of inflammatory diseases. Resveratrol 114-125 interleukin 6 Homo sapiens 208-212 34303665-6 2021 A significant reduction of IL-6 concentration was observed only in the patients receiving >=500 mg/day dose of resveratrol (WMD = -1.89 pg/ml, 95% CI = -3.73 to -0.05, P = 0.04) with inter-study heterogeneity (I2 = 94.4%, P < 0.001). Resveratrol 111-122 interleukin 6 Homo sapiens 27-31 34303665-8 2021 Based on the present findings, resveratrol is able to decrease TNF-alpha and IL-6 (in >=500 mg/day dose) levels but not IL-1 and IL-8 levels. Resveratrol 31-42 interleukin 6 Homo sapiens 77-81 34321087-3 2021 The goal of our study is to figure out whether or how resveratrol (RSV) can protect NPCs from degeneration by affecting IL6/JAK/STAT3 pathway. Resveratrol 54-65 interleukin 6 Homo sapiens 120-123 34321087-3 2021 The goal of our study is to figure out whether or how resveratrol (RSV) can protect NPCs from degeneration by affecting IL6/JAK/STAT3 pathway. Resveratrol 67-70 interleukin 6 Homo sapiens 120-123 34321087-12 2021 Moreover, RSV significantly attenuated the level of IL-6 secretion, which was accompanied by less phosphorylation of the transcription factors Janus kinase 1 (JAK1) and signal transducer and activator of transcription 3 (STAT3). Resveratrol 10-13 interleukin 6 Homo sapiens 52-56 35565270-0 2022 Resveratrol Contrasts IL-6 Pro-Growth Effects and Promotes Autophagy-Mediated Cancer Cell Dormancy in 3D Ovarian Cancer: Role of miR-1305 and of Its Target ARH-I. Resveratrol 0-11 interleukin 6 Homo sapiens 22-26 34227646-3 2021 It was observed that the expression of IL-1beta, IL-6, IL-8 and TNFalpha in LPS-induced HGFs was significantly downregulated by RSV in a dose-dependent manner. Resveratrol 128-131 interleukin 6 Homo sapiens 49-53 34227646-6 2021 Subsequently, it was demonstrated treatment with PI3K/AKT pathway inhibitor (LY294002) or Wnt/beta-catenin pathway inhibitor (Dickkopf-1, DKK-1) could further enhance the anti-inflammatory and antioxidant effects of RSV by downregulating the expression of IL-1beta, IL-6, IL-8 and TNFalpha, and the production of MDA, and increasing the activity of SOD and GSH-Px in LPS-induced HGFs. Resveratrol 216-219 interleukin 6 Homo sapiens 266-270 35565270-5 2022 IL-6 disrupts autophagy in ovarian cancer cells via miRNAs downregulation of ARH-I, an effect contrasted by the nutraceutical protein restriction mimetic resveratrol (RV). Resveratrol 154-165 interleukin 6 Homo sapiens 0-4 35565270-5 2022 IL-6 disrupts autophagy in ovarian cancer cells via miRNAs downregulation of ARH-I, an effect contrasted by the nutraceutical protein restriction mimetic resveratrol (RV). Resveratrol 167-169 interleukin 6 Homo sapiens 0-4 35355720-15 2022 Current evidence supports the antioxidant and anti-inflammatory properties of resveratrol, but its relationship with the levels of some inflammatory cytokines such as IL-6 and TNF-alpha in animals with diabetic nephropathy needs further elucidation. Resveratrol 78-89 interleukin 6 Homo sapiens 167-171